What is the price target for CORT stock?
12 analysts have analysed CORT and the average price target is 68.14 USD. This implies a price increase of 60.36% is expected in the next year compared to the current price of 42.49.
NASDAQ:CORT • US2183521028
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CORCEPT THERAPEUTICS INC (CORT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-26 | Wolfe Research | Upgrade | Underperform -> Peer Perform |
| 2026-03-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-23 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-01-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | UBS | Initiate | Neutral |
| 2025-11-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-11-18 | Wolfe Research | Initiate | Peer Perform |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-09-10 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-01 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-01 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-04-01 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-03-31 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 482.375M 20.02% | 675.04M 39.94% | 761.407M 12.79% | 960M 26.08% | 1.258B 31.04% | 1.521B 20.91% | 1.916B 25.97% | 2.281B 19.05% | 2.465B 8.07% | 2.646B 7.34% | 2.756B 4.16% | |
| EBITDA YoY % growth | 108.324M -4.48% | 137.746M 27.16% | 45.946M -66.64% | 191.98M 317.84% | 170.69M -11.09% | 438.83M 157.09% | 413.41M -5.79% | 460.63M 11.42% | N/A | N/A | N/A | |
| EBIT YoY % growth | 107.282M -4.72% | 136.951M 27.66% | 44.797M -67.29% | 68.946M 53.91% | 393.7M 471.03% | 552.32M 40.29% | 956.19M 73.12% | 1.329B 38.99% | 1.564B 17.68% | 1.692B 8.18% | 1.762B 4.14% | |
| Operating Margin | 22.24% | 20.29% | 5.88% | 7.18% | 31.30% | 36.31% | 49.91% | 58.26% | 63.45% | 63.95% | 63.93% | |
| EPS YoY % growth | 0.95 7.95% | 1.24 30.53% | 0.82 -33.87% | 0.83 0.76% | 2.24 171.11% | 4.39 96.04% | 6.25 42.39% | 8.57 37.08% | 9.68 12.93% | 10.45 7.96% | 10.86 3.95% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.02 -110.80% | 0.16 -43.72% | 0.15 -4.38% | 0.29 42.80% | -0.01 44.44% | 0.27 62.50% | 0.37 140.00% | 0.42 48.21% |
| Revenue Q2Q % growth | 196.36M 24.90% | 230.69M 18.65% | 249.54M 20.18% | 283.41M 40.22% | 232.78M 18.55% | 280.71M 21.68% | 299.83M 20.15% | 317.94M 12.18% |
| EBITDA Q2Q % growth | 31.273M 744.99% | 32.722M 20.10% | 35.557M 220.94% | 41.514M 636.59% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.699M -354.64% | 9.333M -65.01% | 18.987M 85.80% | 42.491M 846.98% | 26.52M 404.88% | 49.368M 428.96% | 76.806M 304.52% | 101.39M 138.62% |
All data in USD
12 analysts have analysed CORT and the average price target is 68.14 USD. This implies a price increase of 60.36% is expected in the next year compared to the current price of 42.49.
CORCEPT THERAPEUTICS INC (CORT) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of CORCEPT THERAPEUTICS INC (CORT) is -0.02 USD and the consensus revenue estimate is 196.36M USD.
The consensus rating for CORCEPT THERAPEUTICS INC (CORT) is 75 / 100 . This indicates that analysts generally have a positive outlook on the stock.